Barely Significant
← all excerpts

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.

ESMO Open · 2026 · PMC13059099 · PMID 41894981

Europe PMCDOI
1
hedged sentence
0.0510
closest p · 1.0× alpha
0.0510
boldest claim

The sentences

borderline significantP = 0.051so close (0.05 < p ≤ 0.1)
A borderline significant OS benefit was observed with FTD–TPI + bevacizumab after accounting for time-dependent effects (Wald test P = 0.051; Supplementary Figure S6 , available at https://doi.org/10.1016/j.esmoop.2026.106907 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.